ULI262
Colorectal Cancer Prevention (initially Familial Adenomatous Polyposis - FAP)
Key Facts
About Curileum Discovery
Curileum Discovery is a preclinical-stage biotech targeting gastrointestinal diseases, specifically colorectal cancer prevention and IBD treatment, through tissue regeneration. Its core asset is ULI262, a novel pan-PPAR agonist small molecule drug aimed at preventing polyp formation in high-risk patients, such as those with Familial Adenomatous Polyposis (FAP). The company is strategically located adjacent to St Mark's Hospital in London and is raising $20 million to fund a first-in-human clinical study in FAP patients starting in 2027. Backed by over 40 years of drug discovery expertise from its founder, Curileum leverages academic and industrial partnerships to advance its pipeline.
View full company profile